Sol SpA Reports Earnings Results for the Year Ended December 31, 2012; Proposes Distribution Payable for 2012
March 28, 2013
Share
Sol SpA reported earnings results for the year ended December 31, 2012. For the period, the company reported net revenue of EUR 582,968,000 compared with EUR 555,711,000 for the same period last year. Total revenues were EUR 599,258,000 compared with EUR 571,428,000 for the same period last year. EBITDA was EUR 132,215,000 compared with EUR 130,428,000 for the same period last year. EBIT was EUR 56,466,000 compared with EUR 59,577,000 for the same period last year. PBT was EUR 46,510,000 compared with EUR 49,771,000 for the same period last year. Net profit was EUR 29,027,000 or EUR 0.320 per share compared with EUR 31,146,000 or EUR 0.343 per share for the same period last year. EBIT was equal to 9.7% on sales due to provisions and non recurring charges for EUR 7.2 million and the increase of depreciation for EUR 3.5 million due to the continual investments program. The capital expenditures of the Group were EUR 85.4 million (CAPEX 14.7%) and the operating consolidated cash flow amounted to EUR 98.5 million. The total net debt was EUR 195.3 million, increased by EUR 20.9 million against 12/31/2011, due to the investments and acquisitions realized.
At the upcoming Shareholders' meeting, called for May 13, 2013 in Monza, the company's Board of Directors will propose distribution of a dividend of EUR 0.10 per ordinary share (equal to 2011), to be paid since May 23, 2012.
SOL SpA is an Italy-based company primarily engaged in the research, production and distribution of industrial, pure and medicinal gases. It is also involved in the home care medical business. The Companyâs product portfolio includes oxygen, nitrogen, hydrogen, argon, sulfur hexafluoride, carbon dioxide, ozone, helium and mixtures of medicinal gases, among others. Through its subsidiaries, the Company is involved in the provision of home care services, such as oxygen therapy, mechanical ventilation, diagnosis and care of obstructive sleep apnea syndrome, artificial nutrition, telemedicine, health assistance, and the prevention and treatment of skin ulcers. Additionally, it is engaged in the supply and management of medical and technological devices for home care. As of December 31, 2011, the Company had a number of subsidiaries, including Airsol BV, Biotechsol Srl, CTS Srl, Energetika ZJ doo, GTH Gaze Industriale SA, Cryolab Srl, GTS Shpk and Hydroenergy Shpk, among others.